Researchers in Ontario have developed a natural delivery system that uses red blood cells to safely carry potent antibiotics to selectively attack and kill bacteria. The breakthrough could help address the increasingly pressing issue of antibiotic resistance.

The team at McMaster University were able to open red blood cells and remove the inner components, leaving only the liposome, which can then be loaded with drug molecules and injected back into the body. They also coated the outside of the membrane with antibodies, allowing it to stick to bacteria and deliver the antibody safely.

The cells were tested carriers for one of the world’s only remaining resistance-proof antibiotics: Polymyxin B (PmB), widely considered a treatment of last resort due to its toxicity and harmful side effects, which include kidney damage.   It is used to fight particularly dangerous and often drug-resistant bacteria such as E. coli, which is responsible for many serious conditions such as pneumonia, gastroenteritis and bloodstream infections.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

“Essentially, we are using red blood cells to conceal this antibiotic within so it can no longer interact or harm healthy cells as it passes through the body,” says Hannah Krivic, a graduate student of biophysics at McMaster and lead author of the study. “We designed these red blood cells so they could only target bacteria we want them to target.”

The team also focused on red blood cells in a previous work because they are stable, sturdy and have a naturally long lifespan—approximately 120 days, giving them ample time to reach different target sites.  “With many traditional drug therapies there are challenges. They tend to degrade rapidly when they enter our circulation system and are randomly distributed throughout our bodies,” Maikel Rheinstädter, a professor in the Department of Physics & Astronomy.  “We often have to take higher doses or repeated doses, which increases exposure to the drug and heightens the risk of side effects.”

Scientists are working on additional applications of the technology, including its potential as a platform to deliver drugs across the blood-brain barrier and directly to the brain, helping patients who suffer from Alzheimer’s or depression, for example, to receive treatment much more quickly and directly. 

The findings were published recently in the journal ACS Infectious Diseases.